Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A once-daily pill for hereditary angioedema just cleared a major hurdle. Pharvaris announced its oral drug deucrictibant reduced monthly swelling attacks by 83% compared to placebo in a late-stage trial — and by 87% in patients with the most common types of the condition. The company plans to file for U.S. approval in the first half of 2027.
Pharvaris scored a big win for patients with hereditary angioedema (HAE) — a rare genetic disorder that causes unpredictable, potentially life-threatening swelling of the face, hands, abdomen, and throat. The company's once-daily oral drug, deucrictibant, met the primary endpoint of its late-stage trial, significantly cutting the frequency of swelling attacks compared to placebo.
The 24-week study enrolled 85 adolescents and adults across 21 countries, covering all three types of HAE. Protection kicked in within the first week and held steady throughout the trial, with a clean safety profile — no serious treatment-related side effects were reported.
By the Numbers:
Why it matters: Current HAE treatments are largely injectable, so a well-tolerated oral option could be a meaningful step forward for patients managing a condition that can turn life-threatening without warning.
